Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Delcath Systems, Inc. is a commercial-stage oncology company focused on the treatment of cancers affecting the liver. The company operates within the biopharmaceutical and medical device industries, developing and commercializing drug-device combination therapies designed to deliver high-dose chemotherapy directly to the liver while limiting systemic exposure. Its core focus is on patients with primary or metastatic liver-dominant cancers for whom existing treatment options are limited.
Delcath’s primary revenue driver is the HEPZATO™ KIT, a proprietary hepatic delivery system used to administer melphalan via isolated hepatic perfusion. The company is uniquely positioned through its specialization in liver-directed oncology therapies and its ownership of an integrated drug-delivery platform. Founded in 1988, Delcath initially developed its technology under the CHEMOSAT® brand in Europe and evolved over time into a focused commercial organization following U.S. regulatory approval of HEPZATO in 2023 for unresectable hepatic metastases from uveal melanoma.
Business Operations
Delcath operates primarily through a single reportable business focused on liver-directed cancer therapies, with commercial activities centered on the sale of HEPZATO™ KIT systems and associated pharmaceutical components. Revenue is generated through direct sales to hospitals and cancer treatment centers, supported by clinical training and implementation services. The company does not currently operate manufacturing facilities at scale, relying instead on specialized third-party manufacturing and distribution partners.
Operations span both domestic and international markets. In the United States, Delcath commercializes HEPZATO following FDA approval, while in Europe the company has historically marketed its technology under the CHEMOSAT® name. The company controls proprietary catheter-based delivery technology and melphalan formulation specific to hepatic administration. Its principal subsidiaries include Delcath Systems Ltd. and Delcath Systems Europe, which support international regulatory, clinical, and commercial activities.
Strategic Position & Investments
Delcath’s strategic direction is centered on expanding adoption of HEPZATO in approved indications while pursuing label expansion into additional liver-dominant cancers. Growth initiatives include increasing the number of treatment centers, investing in physician training programs, and generating post-approval clinical data to support broader reimbursement and guideline inclusion.
The company’s major investment focus is internal, prioritizing commercial infrastructure, clinical research, and regulatory activities rather than large-scale acquisitions. Delcath continues to evaluate emerging applications of hepatic drug delivery and combination oncology approaches but has not disclosed material investments in unrelated sectors. Its portfolio is concentrated around its proprietary hepatic perfusion platform and associated intellectual property.
Geographic Footprint
Delcath is headquartered in North America, with its corporate headquarters in the United States. The company’s primary commercial market is the U.S., where HEPZATO is approved and marketed for a specific oncology indication. Clinical and commercial operations are supported by regional teams focused on major U.S. cancer centers.
Internationally, Delcath maintains a presence in Europe, where its technology has been used under prior regulatory frameworks and commercial agreements. Through its European subsidiaries, the company has historically engaged in distribution, regulatory coordination, and clinical support across multiple European countries, giving it operational reach across North America and Europe.
Leadership & Governance
Delcath is led by an executive team with experience in oncology, medical devices, and pharmaceutical commercialization. Leadership emphasizes disciplined commercialization, regulatory compliance, and focused clinical development within specialized oncology markets.
Key executives include:
- Gerard Michel – President & Chief Executive Officer
- Beatrix Geertz – Chief Financial Officer
- Dr. Jonathan S. Zager – Chief Medical Officer
The board and management team guide corporate strategy with an emphasis on advancing liver-directed cancer therapies and building long-term shareholder value through focused execution in narrowly defined clinical indications.